Costa Rica Advances in Biotech with New Patent for Bone and Muscle Regeneration

By IDEAS

Costa Rica has taken a significant step forward in biomedical innovation with a newly granted patent to the Tecnológico de Costa Rica (TEC), highlighting the growing role of Latin American research institutions in high-impact technologies.

The invention, developed by physicist and researcher Laura Rojas Rojas, is a mechanical stimulation device for human cells that enables advanced research into bone and muscle regeneration—two of the most complex areas in tissue engineering.

One device solving a key scientific limitation

At its core, the patented system allows scientists to stimulate and analyze both bone and muscle cells in a single platform, something that previously required separate equipment.

This integration is not just incremental. It enables experiments that were previously impractical or impossible, opening new pathways in regenerative medicine.

The device replicates conditions inside the human body by controlling:

-temperature and sterile environments

-gas composition, including CO₂ and oxygen

-mechanical movement that mimics natural cellular stress

This mechanical stimulation is critical: it allows cells grown in vitro to develop strength and behavior similar to real human tissue.

The long-term ambition behind the invention is particularly relevant for healthcare systems:
producing bone and muscle grafts in laboratories, instead of extracting them from patients themselves.

If successfully scaled, this could transform treatment for:

-severe trauma cases (e.g., traffic accidents)

-burn victims

-cancer-related tissue loss

-complex reconstructive surgeries

By eliminating the need for autologous grafts, the technology could reduce surgical risks, recovery times, and complications.

A product of long-term research—and IP strategy

The device was developed as part of Rojas’ doctoral research in engineering between 2017 and 2022, with support from multidisciplinary teams working in tissue engineering and biomedicine.

Its patent protection—granted in Costa Rica and valid until 2041—reflects not only its technical novelty but also its industrial applicability, meeting core patentability requirements.

The process was supported by the university’s technology transfer and IP teams, underscoring the increasing sophistication of academic IP management in the region.

Regulatory and commercialization challenges

Despite its promise, the path to clinical application remains complex. Current regulations in Costa Rica limit experimentation with human cells, meaning that international partnerships with universities or private sector actors will likely be necessary to advance the technology toward real-world use.

At the same time, the device is designed to be versatile, with potential applications across:

-biomedical research

-materials science

-physics and engineering